Thong Truong, DPM
Podiatrist · Chico, CANPI 1144336090
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for podiatrist clinicians in CA, where the typical reported total is $730.
Across 19 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$86
- Dexcom, Inc.$57
- Alk-abello, Inc$54
- Biohaven Pharmaceutical Holding Company Ltd.$28
- Sunovion Pharmaceuticals Inc.$25
- Novo Nordisk$23
- plus $106 from 6 others
What the payments were for
- Food & beverage$378100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 3 | $86 |
| Dexcom, Inc. | 3 | $57 |
| Alk-abello, Inc | 3 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Novo Nordisk | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Pfizer | 1 | $20 |
| Exact Sciences | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Smith+Nephew | 1 | $15 |
| Amgen | 1 | $13 |
How this compares
$378 in reported general payments places this provider in the 35th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 110 | $7,729 |
| Gabapentin | 199 | $2,149 |
| Diclofenac Sodium | 198 | $1,718 |
| Terbinafine Hcl | 49 | $778 |
| Ketoconazole | 17 | $606 |
| Triamcinolone Acetonide | 24 | $179 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $147 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $86 |
| Tramadol Hcl | 21 | $48 |
| Meloxicam | 14 | $17 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Chico
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
- David ArmstrongLos Angeles$695K
- Philip WrotslavskyPoway$269K
- Travis WestermeyerEncinitas$158K
- Adrienne EstesPomona$129K
- Ronald LiebermanEncinitas$109K
- Matthew DoyleMountain View$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.